These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B. Lu S; Jang H; Nussinov R; Zhang J Sci Rep; 2016 Feb; 6():21949. PubMed ID: 26902995 [TBL] [Abstract][Full Text] [Related]
7. 1H, 15N and 13C backbone assignments of GDP-bound human H-Ras mutant G12V. Amin N; Chiarparin E; Coyle J; Nietlispach D; Williams G Biomol NMR Assign; 2016 Apr; 10(1):121-3. PubMed ID: 26373425 [TBL] [Abstract][Full Text] [Related]
8. NMR resonance assignments for the active and inactive conformations of the small G protein RalA. Shafiq A; Campbell LJ; Owen D; Mott HR Biomol NMR Assign; 2020 Apr; 14(1):87-91. PubMed ID: 31916136 [TBL] [Abstract][Full Text] [Related]
9. KRAS Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999 [TBL] [Abstract][Full Text] [Related]
10. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681 [TBL] [Abstract][Full Text] [Related]
12. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants. Moghadamchargari Z; Shirzadeh M; Liu C; Schrecke S; Packianathan C; Russell DH; Zhao M; Laganowsky A Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33723061 [TBL] [Abstract][Full Text] [Related]
13. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399 [TBL] [Abstract][Full Text] [Related]
14. Pálfy G; Vida I; Perczel A Biomol NMR Assign; 2020 Apr; 14(1):1-7. PubMed ID: 31468366 [TBL] [Abstract][Full Text] [Related]
15. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate. Gupta AK; Wang X; Pagba CV; Prakash P; Sarkar-Banerjee S; Putkey J; Gorfe AA Chem Biol Drug Des; 2019 Aug; 94(2):1441-1456. PubMed ID: 30903639 [TBL] [Abstract][Full Text] [Related]
16. Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy. Zhao Q; Haga R; Tamura S; Shimada I; Nishida N Sci Rep; 2023 Nov; 13(1):19253. PubMed ID: 37935773 [TBL] [Abstract][Full Text] [Related]
17. Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel. Killoran RC; Smith MJ J Biol Chem; 2019 Jun; 294(25):9937-9948. PubMed ID: 31088913 [TBL] [Abstract][Full Text] [Related]
18. The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Gebregiworgis T; Kano Y; St-Germain J; Radulovich N; Udaskin ML; Mentes A; Huang R; Poon BPK; He W; Valencia-Sama I; Robinson CM; Huestis M; Miao J; Yeh JJ; Zhang ZY; Irwin MS; Lee JE; Tsao MS; Raught B; Marshall CB; Ohh M; Ikura M Nat Commun; 2021 Nov; 12(1):6274. PubMed ID: 34725361 [TBL] [Abstract][Full Text] [Related]
19. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation. Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176 [TBL] [Abstract][Full Text] [Related]
20. KRAS: From undruggable to a druggable Cancer Target. Uprety D; Adjei AA Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]